Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

ogram for the treatment of pain without constipation side effects.  NKTR-102 is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers.  NKTR-105 is in a Phase 1 clinical study in cancer patients with refractory solid tumors. Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect Nektar's current views regarding the potential of its technology platform, the potential of NKTR-102 for breast cancer patients, preliminary results from the Phase 2 clinical trial of NKTR-102 in metastatic breast cancer patients, and the potential of certain other drug candidates in Nektar's pipeline.  These forward-looking statements involve substantial risks and uncertainties, including but not limited to one or more of the following: (i) NKTR-102 is in mid-stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage for one or more of the cancer indications being studied (i.e. ovarian cancer, breast cancer, and colorectal cancer) due to efficacy, safety or other unpredictable factors even after earlier clinical results have been positive; (ii) the Phase 2 data for NKTR-102 in breast cancer in this press release remain subject to audit and confirmation procedures, and the final results may change materially and adversely after such procedures are completed; (iii) additional important data will be reported by Nektar in the future regarding the Phase 2 NKTR-102 clinical study in metastatic breast cancer including but not limited to final progression-free survival and overall survival and therefore the complete and final results for this study may diff
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 2015 CryoLife, Inc. (NYSE: CRY ), ... on cardiac and vascular surgery, announced today the appointment ... position of Senior Vice President, Operations, Quality, and Regulatory, ... to Pat Mackin , Chairman, President, and Chief ... is a seasoned industry executive with over 30 years ...
(Date:4/27/2015)... 2015   AMC Health , a leading provider ... monitored care that are transforming chronic care and population ... Conference, May 2-5 at the Los Angeles ... share information about how their innovative programs, solutions and ... personalize healthcare delivery at Booth #2116 and during their ...
(Date:4/27/2015)... , April 27, 2015 PAML announced ... collaborative agreement with Axela, Inc. to develop multiplex ... diseases. PAML is one of the nation,s leading medical ... acid and protein analysis for clinical diagnostics. ... detection strategies, and assay development serves as the ...
Breaking Medicine Technology:CryoLife Appoints William Matthews as Senior Vice President, Operations, Quality, and Regulatory 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 4PAML and Axela Collaborate on Immune Status for Vaccine Preventable Diseases 2
(Date:4/27/2015)... OH (PRWEB) April 27, 2015 Douglas ... to help his clients feel secure, but also helps secure ... to 7 p.m., Douglas will be manning a booth at ... Center, Lausche Building, 717 E. 17th Ave., Columbus, Ohio. ... worthy event that will feature hundreds of adoptable pets from ...
(Date:4/27/2015)... Ticket Down is a reputable source ... Valley Music Theatre and the Isleta Amphitheater. ... Mexico area can celebrate because their favorite performer will ... Buffett will be performing alongside legendary performers, Huey Lewis ... during the summer and fall months of 2015 are ...
(Date:4/27/2015)... 2015 The global coagulation analyzers ... CAGR in developed countries; however, it is expected ... as China, India and Brazil in the next ... is driven by factors such as increasing adoption ... of high-throughput hemostasis analyzers, developments in high-sensitivity point-of-care ...
(Date:4/27/2015)... 2015 Volpara Solutions today announced ... the Society of Breast Imaging’s SBI/ACR Breast Imaging ... Booth #214). VolparaDensity, the first breast density ... breast tomosynthesis datasets from multiple manufacturers, is already ... and worldwide. , The latest version ...
(Date:4/27/2015)... Puroast Coffee has signed on to sponsor the ... BattleFrog OCR is a series of rigorous courses designed by ... the training that Seals undergo, as well as provide a ... to sponsor the BattleFrog events this year,” says Puroast CEO ... well-suited to give people throughout the country the chance to ...
Breaking Medicine News(10 mins):Health News:Farmers Insurance Agent Douglas Fitzpatrick Ensures Pets Find Homes 2Health News:Cheap Jimmy Buffett Tickets at Alpine Valley Music Theatre in Elkhorn, WI and at Isleta Amphitheater in Albuquerque, NM Now on Sale at TicketDown.com 2Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 2Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 3Health News:Volpara Solutions Releases VolparaDensity 3.1 for Use with Tomosynthesis Systems from Multiple Manufacturers at SBI 2Health News:Volpara Solutions Releases VolparaDensity 3.1 for Use with Tomosynthesis Systems from Multiple Manufacturers at SBI 3Health News:Puroast Coffee on Tour with BattleFrog 2
... Reporter , MONDAY, April 18 (HealthDay News) -- New ... stay clear of AIDS longer if they start drug ... However, starting treatment earlier, compared to waiting, didn,t ... benefit in terms of preventing death" by prescribing the ...
... , MONDAY, April 18 (HealthDay News) -- Patients with ... die after surgery, even after non-emergency procedures, a new study ... be used to revive someone who is clinically unresponsive and ... 18 and in the August print issue of the journal ...
... New research finds that older diabetics with better control of ... as heart attacks, amputation and kidney disease. However, ... sugar levels face a slightly higher chance of dying than ... normal range. Researchers tracked more than 70,000 people with ...
... , MONDAY, April 18 (HealthDay News) -- Infection with ... many college students -- and little exposure to sunlight may ... a new study suggests. "MS is more common at ... researcher, Dr. George C. Ebers, of the University of Oxford ...
... ovarian cancer (HGSOC), the fifth-deadliest cancer among American women, ... fallopian tube malignancy masquerading as an ovarian one. While ... tubes has so far been only circumstantial, a new ... connection, a finding that could aid in the development ...
... Ill. Nearly 800 dental sleep medicine professionals from ... Meeting of the American Academy of Dental Sleep Medicine ... at the Hilton Minneapolis in Minneapolis, Minn. The meeting ... 25th Anniversary Meeting of the Associated Professional Sleep Societies. ...
Cached Medicine News:Health News:Starting HIV Drugs Earlier May Delay AIDS But Not Death 2Health News:Starting HIV Drugs Earlier May Delay AIDS But Not Death 3Health News:People With DNR Orders More Apt to Die After Any Surgery 2Health News:Low Glucose Levels May Raise Death Risk Among Older People 2Health News:Can Common Virus, Lack of Sunlight Boost MS Risk? 2Health News:New scientific model tracks form of ovarian cancer to origins in fallopian tube 2Health News:New scientific model tracks form of ovarian cancer to origins in fallopian tube 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: